Sorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study
F. Mouriaux(Inserm), Florence Joly(Centre François Baclesse), Vincent Servois(Université Paris Sciences et Lettres), Thierry Lesimple, Nicolas Penel(Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), A. Thyss(Centre Antoine Lacassagne), Natacha Heutte(Centre François Baclesse), J J Parienti(Centre Hospitalier Universitaire de Caen Normandie), E M Neidhart-Berard(Centre Léon Bérard), Corinne Delcambre(Centre François Baclesse), A.N.H. Pham(Centre Hospitalier Universitaire de Caen Normandie), Sophie Piperno‐Neumann(Institut Curie)
Cited by 48
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k